Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Normobaric Nocturnal Hyperoxia Therapy for Treating Ischemic-Related Retinal Conditions

NCT03730779 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT03730779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03730779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Normobaric Nocturnal Hyperoxia Therapy for Treating Ischemic-Related Retinal Conditions
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 4
Overall status
Withdrawn
Start date
November 30, 2018
Completion date
January 1, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinal ischemia